New Targets for the Treatment of Hypertension and Associated Diseases

<p>1. The CYP/20-HETE/GPR75 axis in hypertension<br>Ghezal Froogh, Victor Garcia and Michal L. Schwartzman<br>2. Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury<br>John D Imig<br>3. Pharmacological developments in antihypertensive treatment through nitric oxide-cGMP modulation<br>Annika A. Jüttner, A.H. Jan Danser and Anton J.M. Roks<br>4. Sphingosine-1-phosphate and sphingosine-1-phosphate receptors in the cardiovascular system: Pharmacology and clinical implications<br>Simona Federica Spampinato, Maria Angela Sortino and Salvatore Salomone<br>5. Polymorphisms in common antihypertensive targets: Pharmacogenomic implications for the treatment of cardiovascular disease<br>Dominique Brown, Heather Alcala, Peter Oelschlaeger and Bradley T. Andresen<br>6. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension<br>Prasad Chunduri, Shrey A. Patel and Scott P. Levick<br>7. Cardiovascular effects of GLP-1 receptor agonism<br>Raymond J. Winquist and Valentin K. Gribkoff<br>8. ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease<br>HaiFeng Yang and Raouf A. Khalil<br>9. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology<br>Giorgio Minotti, Pierantonio Menna, Massimiliano Camilli, Emanuela Salvatorelli and Roberto Levi</p>